Tamara Braut | Cancer Cell Biology | Innovative Research Award

Posted on by Cell Biologist

Prof. Dr. Tamara Braut | Cancer Cell Biology | Innovative Research Award

Prof. Dr. Tamara Braut | Faculty of Medicine, University of Rijeka/ENT Clinic, Clinical hospital centre Rijeka | Croatia

Professor Tamara Braut, MD, is a renowned Croatian otorhinolaryngologist and Full Professor at the Faculty of Medicine, University of Rijeka. She serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery. Her clinical expertise and academic leadership have significantly contributed to advancements in the diagnosis and treatment of head and neck cancers, particularly laryngeal carcinoma. With over two decades of experience, Dr. Braut is widely recognized for her work in molecular oncology, HPV-associated head and neck tumors, and translational medicine. A frequent collaborator on interdisciplinary and international projects, she is committed to personalized medicine and innovative approaches in clinical research. Her impressive portfolio of peer-reviewed publications, including case studies, multicenter analyses, and biomarker-based diagnostics, highlights her dedication to evidence-based practice and academic excellence. Professor Braut’s academic leadership and clinical insight place her among the top contributors in her specialty within Croatia and internationally.

Publication Profile:

Google Scholar

Strengths For Award:

  • Pioneering work in head and neck oncology and molecular diagnostics

  • Significant publication record in high-impact journals

  • Collaborative multicenter research and precision medicine orientation

  • Demonstrated leadership in academic and clinical settings

  • Integration of clinical insights with research innovation

Areas for Improvement:

  • Broaden research beyond oncology to explore ENT-related AI/technology

  • Increase international collaborations and visibility at global conferences

  • Expand into clinical trials for therapeutics in HPV+ cancers

🎓 Education: 

Prof. Tamara Braut received her Doctor of Medicine (MD) degree from the University of Rijeka, Croatia, where she also completed her specialization in Otorhinolaryngology. Her academic path was distinguished by an early interest in oncology, molecular pathology, and surgical innovation. She pursued postgraduate training and research with a focus on laryngeal and head and neck cancers. Throughout her education, she was actively involved in academic research, participating in numerous national and international conferences, which sharpened her analytical and investigative skills. She later obtained her PhD with a focus on molecular markers in squamous cell carcinoma. Over the years, she has pursued continuous professional development in precision medicine, oncology biomarkers, and evidence-based surgical practices. Her academic and clinical training has made her a highly competent physician-scientist, well-versed in both patient care and experimental research.

🧑‍🔬 Experience:

Prof. Tamara Braut has over two decades of experience in clinical and academic medicine. She currently serves as the Head of the Department of Otorhinolaryngology and Head and Neck Surgery at the Faculty of Medicine, University of Rijeka. Her career spans clinical work, academic leadership, surgical practice, and scientific research. She has treated complex cases involving laryngeal and head-neck cancers and has led multidisciplinary teams in oncology care. As an educator, she has supervised medical students, residents, and PhD candidates, many of whom now hold academic and clinical positions. Dr. Braut is a prolific researcher, contributing to over 40 peer-reviewed articles, case studies, and reviews. Her leadership in multicenter studies and her role as a principal investigator in several clinical research projects highlight her competence in collaborative and innovative medical research.

🔬 Research Focus:

Prof. Braut’s research focus lies at the intersection of head and neck oncology, molecular diagnostics, and personalized medicine. She has a keen interest in biomarker discovery, especially in HPV-positive head and neck squamous cell carcinomas, and the role of EGFR signaling pathways in cancer progression. Her work includes translational research linking clinical findings with molecular data to improve prognosis, diagnosis, and treatment strategies. She has also explored the impact of hormonal therapies, gene expression markers like Ki-67 and IMP3, and novel imaging and diagnostic tools. In recent years, she has expanded her interest to gastroesophageal reflux disease and its implications in ENT disorders. Her contributions reflect a consistent commitment to advancing precision medicine, long-term patient follow-up, and multimodal treatment outcomes. She continues to integrate research into clinical practice, thereby fostering innovation and improved patient care in the otorhinolaryngology field.

📚 Publications List Top Notes:

  1. 🧬 Laryngeal SCC shows stronger Nectin-4 vs Nectin-2 expression – CIMB (2025)

  2. 🥗 GERD Management: From PPIs to Diet & Lifestyle – Gastrointest. Disord. (2025)

  3. 🔍 Advances in HPV-Positive Head & Neck Cancer Diagnostics – Biomolecules (2024)

  4. 🧪 Biomarkers in HPV+ Head and Neck SCC: Precision Medicine – Diagnostics (2024)

  5. 💉 Testosterone Therapy in Advanced Head & Neck SCC – Crit. Rev. Oncol. Hematol. (2023)

  6. 🏥 Long-Term Care in Laryngeal Cancer: Multicenter Analysis – J Pers. Med (2023)

  7. 📊 5-Year Clinical Course in Laryngeal Tumors – Acta Clin. Croatica (2022)

  8. 🧫 Renal Cell Carcinoma Metastasis to Larynx: Rare Case – Medicina Flum (2021)

  9. 🧠 Posttraumatic Vernet Syndrome without Fracture: Case Study – Medicine (2021)

  10. ⚛️ Nuclear EGFR Expression = Poor Survival in Laryngeal Ca – AIMM (2021)

Conclusion:

Prof. Tamara Braut is highly deserving of the Innovative Research Award. Her work showcases originality, clinical relevance, and scientific depth. With a robust academic and clinical foundation, she continues to push the boundaries in ENT oncology and diagnostics.

 

wenhao chen | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. wenhao chen | Cancer Cell Biology | Best Researcher Award

Prof. wenhao chen , Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health , China

Dr. Wenhao Chen, a leading orthopedic surgeon and researcher, currently serves as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine. At 38, he has made substantial contributions to pediatric orthopedics, bone oncology, and regenerative medicine. Dr. Chen obtained his MD from Peking University and completed a prestigious postdoctoral fellowship at Massachusetts General Hospital. Known for integrating clinical expertise with biomedical research, he has authored over 17 high-impact papers, applying advanced techniques such as machine learning, gene profiling, and CRISPR screening in orthopedic studies. His work spans rare skeletal diseases, cancer metastasis, and spinal cord repair. Recognized internationally, he continues to mentor young researchers and lead translational projects. With a vision toward improving musculoskeletal health in children, his multidisciplinary approach positions him as a strong contender for the Best Researcher Award.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Outstanding Research Productivity:
    Dr. Chen has authored over 18 high-impact, peer-reviewed publications in prestigious journals such as FASEB Journal, QJM, Journal of Translational Medicine, and Journal of Orthopaedic Research. His work spans orthopedics, oncology, regenerative medicine, and computational biology.

  2. Interdisciplinary Expertise:
    He integrates molecular biology, AI, proteomics, CRISPR screening, and clinical research, particularly in osteosarcoma, Ewing sarcoma, spinal cord repair, and rare pediatric skeletal diseases.

  3. Clinical and Academic Leadership:
    As Head of the Department of Orthopedics at a leading children’s hospital and faculty member at Zhejiang University, he demonstrates clinical leadership and research excellence.

  4. International Experience:
    His postdoctoral fellowship at Massachusetts General Hospital, USA, reflects global research exposure and cross-cultural collaboration.

  5. Translational Impact:
    Dr. Chen’s research shows a clear clinical application, such as prognosis prediction models, radiotherapy effectiveness evaluation, and gene therapy strategies for rare disorders and cancer.

🔧 Areas for Improvement:

  1. Visibility in Global Academic Forums:
    While his research is impactful, increased participation in international conferences, workshops, and symposiums could enhance visibility and networking.

  2. First-/Last-Author Publications:
    While present, a greater proportion of senior authorship could strengthen his recognition as a principal investigator or thought leader in major studies.

  3. Grant Leadership & Patent Output:
    There’s limited publicly shared information on research grants led or intellectual property (e.g., patents), which could further validate his innovation and translational output.

🎓 Education:

Dr. Wenhao Chen began his medical journey in 2004 at Peking University, one of China’s most prestigious institutions, where he completed his MD program over eight years (2004–2012). This comprehensive training gave him a robust foundation in clinical medicine and surgical practice. As part of his pursuit of global excellence, Dr. Chen was selected for a postdoctoral research position at Massachusetts General Hospital (2019–2020), affiliated with Harvard Medical School. During this international fellowship, he engaged in advanced research in orthopedics, including joint reconstruction, stem cell applications, and musculoskeletal oncology. His education reflects not only academic brilliance but also an openness to cross-border scientific collaboration. Dr. Chen’s diverse educational background enables him to merge Eastern clinical insights with Western research innovations, which he continues to apply in developing pediatric orthopedic interventions and understanding skeletal disorders on a molecular level.

💼 Experience:

With over a decade of experience in clinical orthopedics and research, Dr. Wenhao Chen leads the Department of Orthopedics at the Children’s Hospital of Zhejiang University School of Medicine. His career began in top-tier clinical hospitals in China and expanded to the U.S. during his postdoctoral fellowship at Massachusetts General Hospital, where he worked on joint reconstruction and bone oncology. In his current leadership role, he spearheads surgical treatment strategies, oversees translational research projects, and mentors medical trainees. Dr. Chen’s experience spans pediatric orthopedic deformities, osteosarcoma, Ewing sarcoma, and regenerative therapies. He’s an expert in the application of genomics, CRISPR screens, and AI in musculoskeletal disorders. His multidisciplinary projects have led to multiple grants and collaborations. Dr. Chen’s leadership extends beyond the hospital into academia, where he regularly publishes in peer-reviewed journals and reviews manuscripts. His balance of surgical excellence and innovation defines his professional experience.

🔬 Research Focus:

Dr. Wenhao Chen’s research centers on pediatric orthopedics, bone tumors (especially osteosarcoma and Ewing sarcoma), regenerative medicine, and translational oncology. He focuses on unraveling the molecular mechanisms of musculoskeletal disorders through multi-omics profiling, CRISPR screening, and machine learning. A significant part of his work addresses prognostic modeling using genomic and metabolic markers. He has also pioneered studies on gene therapy using viral vectors for spinal cord repair and the application of stem cells in congenital skeletal diseases like mucopolysaccharidosis IVA. Additionally, he investigates inflammation and autophagy signaling pathways, notably the PI3K/AKT/GSK3β axis in bone homeostasis. His translational research aims to convert biological findings into targeted clinical therapies. Dr. Chen’s work is consistently published in top-tier journals and has influenced diagnostic and therapeutic protocols in orthopedics. His blend of computational biology, clinical acumen, and lab innovation defines his impactful and forward-looking research portfolio.

📚 Publications Top Notes:

  1. 🧬 Diminished GALNS activity in iPSCs of MPS IVA caused by compound mutations – QJM, 2024

  2. 🧪 LARS as essential gene for osteosarcoma proliferation via CRISPR screening – J Transl Med, 2022

  3. 🌬️ Itraconazole mitigates lung fibrosis via SPP1/C3 signaling – J Transl Med, 2024

  4. 🔬 Chaperone-mediated autophagy protects bone formation via PI3K/AKT pathway – FASEB J, 2024

  5. 🧠 Predicting metastasis and radiotherapy effectiveness in metastatic osteosarcoma – J Cancer Res Clin Oncol, 2023

  6. 🤖 Machine learning predicts prognosis in Ewing sarcoma patients – J Orthop Res, 2021

  7. ⚡ Glycolysis-related gene score predicts osteosarcoma survival – J Orthop Res, 2022

  8. 🧫 Candidate proteins for astrocyte-to-neuron conversion via proteomics – Neural Regen Res, 2021

  9. 🦴 Surgery ± radiotherapy for malignant giant cell tumor of bone/soft tissue – J Orthop Res, 2020

  10. 🧠 NeuroD1 gene promotes glial-to-neuron conversion post-spinal cord injury – Brain Res Bull, 2017

🧾 Conclusion:

Dr. Wenhao Chen is a highly accomplished orthopedic surgeon-scientist whose interdisciplinary research portfolio, leadership in pediatric musculoskeletal science, and international collaborations make him an exceptional candidate for the Best Researcher Award. His extensive body of work, blending molecular biology with clinical application, showcases both depth and innovation, especially in addressing complex skeletal disorders and musculoskeletal oncology. With a few enhancements in international visibility and grant leadership, he is well on the path to becoming a global leader in orthopedic research.

Zu-Chian Chiang | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Dr. Zu-Chian Chiang | Cancer Cell Biology | Best Researcher Award

Dr. Zu-Chian Chiang , Fujian Normal University , China

Dr. Zu-Chian Chiang is a highly accomplished postdoctoral fellow at the Biomedical Research Center of Southern China, Fujian Normal University, specializing in cancer research and regenerative medicine. With extensive experience in antibody-drug conjugates (ADCs), peptide synthesis, and tissue engineering, his work focuses on the development of targeted therapies and innovative biomaterials for medical applications. Dr. Chiang’s expertise includes both academic research and real-world clinical applications, and he has contributed to numerous peer-reviewed publications and conference presentations. Over the years, his research has received recognition from prestigious institutions such as the National Taiwan University and Academia Sinica. He also plays an active role in academic societies, providing his expertise as a peer reviewer for various scientific journals and as a key member of multiple international organizations. Dr. Chiang continues to make significant strides in biomedical engineering and cancer therapy.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Education and Experience:

    • Dr. Chiang has a robust academic background, with a Ph.D. in Materials and Chemical Engineering and an M.S. in Chemistry, both from reputable institutions in Taiwan. His postdoctoral experience spans multiple prestigious institutions, such as Academia Sinica and National Taiwan University Hospital, and his ongoing postdoc at the Biomedical Research Center of Southern China showcases his continued dedication to scientific progress.

  2. Research Excellence:

    • Dr. Chiang has made significant contributions to the field of cancer research, particularly in antibody-drug conjugates (ADCs), functional peptides for cancer research, and the development of specific aptamers as targeted therapies for cancer.

    • He has authored numerous high-quality peer-reviewed publications (with recent impactful papers), contributing to advancing understanding in immunotherapy, ADCs, and cancer therapeutics. His research has garnered attention in journals like Frontiers in Oncology and PLOS ONE.

  3. Awards and Recognition:

    • Dr. Chiang’s receipt of multiple prestigious awards, such as the 3rd Biotech Elite Training Reserve Program award, highlights his excellence in both academic and professional research. His achievements have earned recognition from both Taiwanese and Chinese scientific communities.

  4. Active Contribution to the Scientific Community:

    • Serving as a peer reviewer for the International Journal of Biological Macromolecules, as well as being involved in numerous scientific societies, demonstrates his commitment to advancing the field and his active engagement with the wider scientific community.

  5. Research Support and Funding:

    • Dr. Chiang has successfully secured research funding from prominent sources, such as the Department of Human Resources and Social Security, Fujian Province, showcasing his ability to lead and manage significant research projects. His ongoing research projects reflect a focus on cancer therapies and therapeutic advancements, further cementing his relevance in the field.

Areas for Improvement:

  1. Public Engagement and Outreach:

    • While Dr. Chiang has impressive research achievements, further expanding his presence in broader public engagement, such as science communication, could help make his findings accessible to a larger audience, especially in cancer therapy and regenerative medicine.

  2. Collaboration and Networking:

    • Dr. Chiang’s research has been highly productive, but future collaboration with other interdisciplinary teams could increase the breadth of his work and facilitate the development of novel, cross-disciplinary solutions.

  3. Increasing Citation Impact:

    • Although Dr. Chiang has 91 citations, his h-index of 5 suggests there may be room to increase the visibility and citation impact of his work. Strategic publishing in highly-cited journals or working with larger collaborative projects could elevate this metric.

  4. Mentorship and Training:

    • While his extensive postdoctoral training is impressive, Dr. Chiang’s experience in mentorship or leading research teams could be enhanced further. Serving as a mentor for students and junior researchers could help strengthen his leadership in the scientific community.

Education:

Dr. Zu-Chian Chiang earned his Ph.D. in Materials and Chemical Engineering from National United University, Taiwan (2008-2014), where he specialized in biomedical engineering under the mentorship of Professor An-Chong Chao and Dr. Guo-Chung Dong. Prior to that, he completed his M.S. in Chemistry from Tunghai University, Taiwan (2005-2007), under the guidance of Professor Feng-Di Lung. His doctoral research focused on creating innovative materials for biomedical applications, such as scaffolds for tissue engineering. Throughout his academic career, Dr. Chiang was awarded scholarships and fellowships recognizing his excellence in research, such as the First Outstanding Doctoral Scholarship at National United University and the Master’s Program Scholarship from the Hunan Fellow Association of Taiwan. His academic foundation laid the groundwork for his cutting-edge contributions to cancer research, drug delivery, and regenerative medicine, ensuring his continued impact in the field.

Experience:

Dr. Zu-Chian Chiang has accumulated a wealth of research experience, serving as a postdoctoral fellow at various prestigious institutions. Since September 2019, he has been working at the Biomedical Research Center of Southern China, Fujian Normal University, focusing on cancer therapies and advanced drug delivery systems. Prior to this, he held postdoctoral positions at the Institute of Biological Chemistry, Academia Sinica (2016-2019), and National Taiwan University Hospital’s Clinical Trial Center (2015-2016), where he worked on pioneering biotechnological projects, including the Taiwan Protein Project. Dr. Chiang’s expertise extends to developing antibody-drug conjugates (ADCs), functional peptides, and biomaterials for regenerative medicine. His involvement in various research groups has strengthened his interdisciplinary knowledge in both molecular and clinical aspects of cancer therapy. Dr. Chiang also gained valuable teaching experience while completing his degrees, serving as a teaching assistant in organic chemistry and chemical engineering courses throughout his academic career.

Awards and Honors:

Dr. Zu-Chian Chiang has received numerous prestigious awards throughout his career, reflecting his significant contributions to the field of biomedical research. Notable honors include the “Science and Technology Commissioner” title in Quanzhou, Fujian Province (2020), and the “Miaoli Southeastern Xindong Satellite Rotary Club Chairman Award” (2017). In 2016, he was honored as an awardee of the “3rd Biotech Elite Training Reserve Program” by National Taiwan University and Taiwan’s Ministry of Science and Technology. His academic achievements were further recognized with the Chung Hwa Rotary Annual Doctoral Program Award (2012), and he received the First Outstanding Doctoral Scholarship at National United University (2010). Additionally, Dr. Chiang was awarded the Master’s Program Scholarship from the Hunan Fellow Association of Taiwan (2007). These accolades reflect his outstanding dedication to scientific research, education, and professional development in the fields of cancer therapy and regenerative medicine.

Research Focus:

Dr. Zu-Chian Chiang’s primary research interests lie in the development of functional peptides for cancer therapy and tissue engineering, as well as the design of advanced biomolecular materials for regenerative medicine. His work focuses on antibody-drug conjugates (ADCs), targeting specific cancer cells for more effective therapies. One of his key research areas is developing specific aptamers as blockers, agonists, or antagonists for cancer treatment, aiming to enhance therapeutic outcomes. He is also dedicated to the synthesis of peptides that can aid in the regeneration of bone tissue and the creation of biomaterials that combine bioactive molecules for regenerative medicine. Through his research, Dr. Chiang aims to improve cancer treatments by targeting tumors more precisely, reduce side effects, and contribute to breakthroughs in drug delivery. His work also explores innovative methods of using biomaterials for enhancing regenerative medicine, thus bridging the gap between basic science and clinical application.

Publications Top Notes:

  1. “Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects” 🧬💉

  2. “Strengthening effect of thalidomide combined with anti-PD1 antibody on enhancing immunity for lung cancer therapy” 🫁💪

  3. “Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo” 🫀⚛️

  4. “Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells” 🧪🧫

  5. “Preparation and characterization of dexamethasone-immobilized chitosan scaffold” 💊🧵

  6. “Characterization of the morphology and hydrophilicity of chitosan/caffeic acid hybrid scaffolds” 🧫🌿

  7. “Preparation and characterization of caffeic acid grafted chitosan/CPTMS hybrid scaffolds” 🍄🔬

Conclusion:

Dr. Zu-Chian Chiang is a highly qualified and accomplished researcher, with a strong track record in cancer research and therapeutic innovation. His work in developing antibody-drug conjugates, functional peptides, and aptamers demonstrates great promise in transforming cancer therapy. His academic credentials, publications, awards, and research funding solidify his standing as a top candidate for the Best Researcher Award. Further expansion into public engagement, interdisciplinary collaborations, and mentorship could further enhance his contributions to the field and his overall impact. Therefore, Dr. Chiang is certainly a strong contender for the award, with potential for even greater influence moving forward.

Dominique Heymann | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Prof. Dr. Dominique Heymann | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Dominique Heymann , Nantes Université, CNRS, Institut de Cancérologie de l”Ouest , France

Professor Dominique Heymann is a highly esteemed academic and clinician, specializing in histology, embryology, and oncology. He is a Professor at Nantes University, France, and a Hospital Practitioner at the ICO Cancer Centre. With a wealth of experience in bone oncology and cancer research, he is also an Honorary Professor at the University of Sheffield, UK. His expertise spans from cell biology to immunology and biochemistry, and he is dedicated to advancing cancer research, particularly in the field of bone tumors and osteosarcoma. With numerous publications to his name and contributions to the global scientific community, Professor Heymann is recognized for his groundbreaking work in cell signaling and tumor progression. He is a valued researcher in the oncology community, with a strong focus on developing innovative therapies for cancer treatment.

Publication Profile:

Google Scholar

Strengths for the Award:

Professor Dominique Heymann is a distinguished figure in the field of oncology, particularly bone oncology, with a strong focus on the molecular mechanisms of bone tumors like osteosarcoma. His academic and clinical roles at the University of Nantes and the ICO Cancer Centre underscore his leadership in research and patient care. He has contributed significantly to understanding tumor biology, bone remodeling, and regenerative medicine, making him a highly respected expert in these fields. His research addresses crucial topics such as circulating tumor cells, targeted therapies, and the development of new anticancer agents, all of which are of immense value to advancing cancer treatment. With multiple publications in prestigious journals, including studies on novel therapies and molecular pathways in cancer progression, Professor Heymann has demonstrated exceptional scientific rigor. His global collaborations and recognition further establish him as a leading researcher in cancer biology and oncology.

Areas for Improvements:

Despite his numerous contributions, there are a few areas where Professor Heymann’s research could evolve. While he has made notable strides in cancer treatment and bone oncology, expanding research into more personalized medicine approaches and exploring the integration of AI and machine learning in predictive oncology could enhance the applicability of his findings. Furthermore, increasing collaborative efforts with international interdisciplinary teams could yield broader insights, especially in rare cancers and metastasis research. Developing a more extensive outreach to clinical trials and collaborations in broader regions may also allow for faster translation of his research into practice.

Education:

Professor Heymann began his academic journey at Paris VII University, where he earned a Master’s degree in Cell Biology in 1991. His PhD in Cell Biology and Immunology was completed at Nantes University in 1995, a pivotal moment in his career. Further expanding his knowledge, he pursued research management abilities and a deeper focus on Biochemistry and Cell Biology at Nantes University in 1998. He also received specialized certification in Histology from Nantes University in 1999 and later completed the required authorizations for animal experimentation in 2003 and 2016. Throughout his academic career, Professor Heymann has continually updated his qualifications, ensuring his expertise remains at the cutting edge of medical and biological sciences. His academic foundation has underpinned his significant contributions to cancer research, with a strong emphasis on bone oncology and regenerative medicine.

Experience:

Professor Dominique Heymann has an extensive and diverse career spanning several decades in both academic and clinical settings. Currently, he serves as a Professor of Histology/Embryology at Nantes University and as a Hospital Practitioner at the ICO Cancer Centre, where he is instrumental in patient care and research. His professional trajectory includes significant roles in oncology, particularly focused on bone tumors, osteosarcoma, and regenerative medicine. As an Honorary Professor at the University of Sheffield, he extends his influence beyond France, fostering international collaboration in cancer research. Professor Heymann has been a prominent figure in multiple research projects, having managed and contributed to groundbreaking studies. His expertise in cancer biology, combined with his academic roles, has allowed him to mentor students and researchers, shaping the next generation of scientists. His dual role in academia and clinical practice makes him a leading figure in both spheres.

Awards and Honors:

Professor Dominique Heymann’s career is adorned with numerous accolades and honors. As a tenured professor at the University of Nantes, he has received recognition for his contributions to histology, embryology, and oncology. He was appointed as an Honorary Professor in Bone Oncology at the University of Sheffield, UK, an esteemed acknowledgment of his expertise in the field. His work in cancer research, particularly related to bone tumors, has earned him international recognition, and his published studies continue to be highly regarded in scientific journals. Additionally, Professor Heymann has contributed significantly to the understanding of osteosarcoma and bone regeneration, which has earned him awards from academic and clinical societies. His continuous impact in advancing the field through groundbreaking research, leadership in clinical oncology, and educational contributions has made him a highly respected figure in the medical and scientific communities.

Research Focus:

Professor Dominique Heymann’s research is focused on cancer, particularly bone tumors such as osteosarcoma, and the molecular mechanisms involved in bone regeneration. His work primarily investigates the signaling pathways that control bone remodeling, the interactions between tumor cells and the microenvironment, and the role of immune responses in bone diseases. One of his key research interests is the development of targeted therapies to combat cancer progression, with a special emphasis on novel anticancer agents, including glycosaminoglycan-mimetic compounds derived from marine bacterial exopolysaccharides. In addition, Professor Heymann is dedicated to studying the role of circulating tumor cells as predictive markers for drug resistance and tumor progression. His expertise also includes stem cell therapies, autophagy in osteoblasts, and the potential for therapeutic applications in bone repair and regeneration. His research aims to improve patient outcomes through innovative approaches in cancer treatment and bone health.

Publications Top Notes:

  • Heymann D, Muñoz-Garcia J, Babuty A, et al. A new promising anticancer agent: a glycosaminoglycan-mimetic derived from the marine bacterial infernan exopolysaccharide. Int J Biol Macromol. (in press) 🧬

  • Jacquot P, Muñoz-Garcia J, Léger A, et al. A multispecific checkpoint inhibitor Nanofitin with a fast tumor accumulation property and antitumor activity in immune competent mice. Biomolecules. (in press) 🔬

  • Yadav P, Heymann D, Prasad RN. Circulating tumor cells: a predictive marker for drug resistance and tumor progression. Front Oncol. (in press) 🔬

  • Muñoz-Garcia J, et al. Interleukin-34 orchestrates bone formation through its binding to Bone Morphogenic Proteins. Theranostics. 2025; 15(7):3185-3202. 🦴

  • Young RJ, et al. CIRCUS: CIRCUlating tumor cells in soft tissue Sarcoma – a short report. Cancer Drug Resist. 2022; 4:51. 💉

  • Oliver L, et al. Transcriptional landscape of the interaction of human mesenchymal stem cells with glioblastoma in bioprinted co-cultures. Stem Cell Res Ther. 2024; 15(1):424. 🧫

  • Cordova LA, et al. Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care? Osteoporos Int. 2024; 35(9):1677-1678. 🦷

  • Childs A, et al. A prospective observational cohort study for newly diagnosed patients in the UK: ICONIC study initial results. Cancers (Basel). 2024; 16(13):2351. 📊

  • Rey V, et al. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma. EBioMedicine. 2024; 102:105090. 🧬

  • Jubelin C, et al. Identification of MCM4 and PKRDC as new regulators of osteosarcoma cell dormancy based on 3D cultures. BBA Mol Cell Res. 2024; 1871:119660. 🧪

Conclusion:

Professor Dominique Heymann’s expertise in oncology, histology, and embryology positions him as an outstanding candidate for the Research for Best Researcher Award. His achievements in cancer research, particularly in bone tumors, and his contributions to advancing the understanding of tumor biology make him an exemplary figure. While there are areas to expand in terms of interdisciplinary collaborations and technological integration, his exceptional body of work and his dedication to both academic excellence and clinical practice make him a deserving candidate for this prestigious award.

Jacob Wekalao | Cancer Cell Biology | Best Researcher Award

Posted on by Cell Biologist

Mr. Jacob Wekalao | Cancer Cell Biology | Best Researcher Award

Mr. Jacob Wekalao , USTC CHINA , China

Jacob Wekalao is a Physics professional and researcher with extensive experience in both academia and industry. He holds a Doctor of Philosophy from the University of Science and Technology and a Master of Science in Physics from Marwadi University, India. Jacob has worked as a physics teacher, leading the physics department at Kwale High School, Kenya, and is currently a software expert at Eujim Solutions, where he specializes in creating innovative business solutions. He is also a Research Assistant at Marwadi University, contributing to advanced research in physics and nanotechnology. His expertise spans across terahertz sensors, graphene-based biosensors, and surface plasmon resonance techniques. In addition to his academic endeavors, Jacob has authored several peer-reviewed publications, showcasing his contributions to forensic science, health, and biomedical applications. Jacob is passionate about research, mentoring, and leveraging technology to solve real-world problems.

Publication Profile:

Orcid

Strengths for the Award:

Jacob Wekalao is an exceptional researcher in the field of experimental physics, particularly in the areas of nanotechnology, terahertz sensors, and biosensing. His work integrates cutting-edge research with practical applications, demonstrating a high level of innovation and expertise. Jacob’s contributions to the development of graphene-based sensors for various applications, including healthcare, forensic science, and security, have positioned him as a thought leader in his field. His published works in prestigious journals and his active role in research projects, such as designing biosensors for early disease detection, highlight his proficiency in both theoretical and applied physics. Additionally, Jacob’s ability to collaborate internationally and present at major conferences reflects his commitment to advancing scientific knowledge and networking within the global research community.

Areas for Improvement:

While Jacob excels in his research and technological expertise, expanding his focus on interdisciplinary collaborations could further elevate his work. Engaging more with industry experts in areas like artificial intelligence or machine learning could also open doors for more transformative innovations, especially in optimizing sensor technologies. Further involvement in policy or public science initiatives could help bridge the gap between research and broader societal applications.

Education:

Jacob Wekalao has an impressive educational background that supports his expertise in physics and technology. He is currently pursuing a Doctor of Philosophy at the University of Science and Technology, China. His academic journey began with a Bachelor of Education in Science with a focus on Physics and Mathematics from the University of Embu, Kenya (2016-2020). This solid foundation propelled him to obtain a Master of Science in Physics from Marwadi University, Rajkot, Gujarat, India (2021-2023). During his time at Marwadi University, Jacob excelled academically, earning an Academic Gold Medal in November 2023 for his outstanding performance. His commitment to learning is also reflected in certifications from institutions like KAIST and the Israel Institute of Technology. Jacob’s education is characterized by a blend of theoretical knowledge and practical skills, which has enabled him to contribute significantly to the fields of experimental physics and applied technology.

Experience:

Jacob Wekalao has diverse experience spanning education, research, and industry. From September 2019 to August 2021, he worked as a Physics teacher at Kwale High School, Kenya, where he led the physics department, developed curriculum materials, and managed science projects. This role enabled him to foster critical thinking and scientific inquiry among students. In addition to his teaching experience, Jacob is currently employed as a Software Expert at Eujim Solutions, Kenya (July 2023 – Present), where he provides tailored software solutions, improves business efficiency, and implements cutting-edge technologies. Furthermore, he works as a Research Assistant at Marwadi University, collaborating on various physics research projects focused on terahertz sensors and biosensors. His involvement in multiple projects and publications has established him as a valuable contributor to advancements in technology and scientific research. Jacob’s work showcases a seamless integration of theoretical physics and practical application in technology.

Awards and Honors:

Jacob Wekalao’s dedication to academic excellence and research has earned him notable awards and honors. He received the prestigious Academic Gold Medal from Marwadi University, Rajkot, India, in November 2023, recognizing his exceptional performance in the Master of Science in Physics program. Jacob’s achievements are further validated by his numerous peer-reviewed publications, which have contributed to the global scientific community. His research in the fields of biosensing, terahertz technology, and nanomaterials has earned him recognition at various international platforms. In addition to academic awards, Jacob’s work has been presented at leading conferences, such as the International Conference on Chemical Safety and Security for Health and Environment (ICCSSHE), held in India in December 2023. His strong academic performance, leadership in research, and contributions to technological advancements continue to set him apart as an outstanding professional in his field.

Research Focus:

Jacob Wekalao’s research focuses on experimental physics, particularly in the areas of terahertz technology, biosensing, and nanomaterials. His work has significant implications for applications in healthcare, security, and forensic science. Jacob has developed and optimized graphene-based terahertz surface plasmon resonance sensors for the detection of various biomolecules, including hemoglobin and illicit drugs. His research has extended to the design of graphene metasurfaces for efficient detection of diseases like malaria and COVID-19. Jacob’s research in biosensors has led to highly sensitive, cost-effective solutions that hold promise for point-of-care diagnostics and environmental monitoring. Additionally, his work on the use of metasurfaces for explosive detection has practical implications for security. Through his research, Jacob combines advanced theoretical physics with real-world applications, contributing to the fields of biomedical technology, environmental monitoring, and security. His interest in machine learning also aids in optimizing these sensor technologies for better precision and performance.

Publications Top Notes:

  1. “Graphene-based THz surface plasmon resonance biosensor for hemoglobin detection applicable in forensic science.” 📖🔬
  2. “Design of ring and cross-shaped graphene metasurface sensor for efficient detection of malaria and 2-bit encoding applications.” 🦠🔍
  3. “Waterborne bacteria detecting highly sensitive graphene metasurface-based cost-efficient and efficient refractive index sensors.” 💧🔬
  4. “Design of graphene metasurface sensor for efficient detection of COVID-19.” 🦠💡
  5. “Graphene biosensor design based on glass substrate for forensic detection of illicit drugs.” 💊🔍
  6. “Graphene and Gold Metasurface-Based Terahertz Surface Plasmon Resonance Sensor for Explosive Detection.” 💥🛡️
  7. “Terahertz Optical Ultrasensitive Glucose Detection Using Graphene and Silver Surface Plasmon Resonance Metasurfaces for Biomedical Applications.” 🩺🔬
  8. “High-Sensitivity Graphene-Gold Metasurface Optical Biosensor for Early Melanoma Detection Optimized with Machine Learning Using a One-Dimensional Convolutional Neural Network and Binary Encoding.” 🧬🔬

Conclusion:

Jacob Wekalao’s contributions to the fields of physics and technology demonstrate an impressive combination of academic excellence, hands-on expertise, and innovative solutions. His drive to advance scientific knowledge and apply it for real-world impact, especially in healthcare and security, makes him a deserving candidate for the Best Researcher Award. Jacob’s ongoing work on high-sensitivity biosensors and his ability to stay ahead of technological trends make him a standout researcher in his field.